Long-Term outcomes of ablative stereotactic body radiation therapy for inoperable, non-metastatic pancreatic cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
88 patients with inoperable non-metastatic PC who underwent ablative 5-fraction SBRT using a CyberKnife with fiducial-based respiratory tracking between 2016 and 2020.
I · Intervention 중재 / 시술
ablative 5-fraction SBRT using a CyberKnife with fiducial-based respiratory tracking between 2016 and 2020
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Grade 3 gastrointestinal bleeding occurred in four patients (4.5 %), with no grade ≥ 4 toxicities observed. [CONCLUSION] Ablative 5-fraction SBRT with BED ≥ 100 Gy results in favorable survival and acceptable toxicity in inoperable, non-metastatic PC.
[PURPOSE/OBJECTIVE(S)] To evaluate long-term outcomes and tolerability of ablative 5-fraction stereotactic body radiation therapy (SBRT) administering a biologically effective dose (BED, α/β = 10) ≥ 1
- 95% CI 14.1-23.4
- 추적기간 64.0 months
APA
Cao BY, Zhang LT, et al. (2025). Long-Term outcomes of ablative stereotactic body radiation therapy for inoperable, non-metastatic pancreatic cancer.. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 213, 111210. https://doi.org/10.1016/j.radonc.2025.111210
MLA
Cao BY, et al.. "Long-Term outcomes of ablative stereotactic body radiation therapy for inoperable, non-metastatic pancreatic cancer.." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, vol. 213, 2025, pp. 111210.
PMID
41110804 ↗
Abstract 한글 요약
[PURPOSE/OBJECTIVE(S)] To evaluate long-term outcomes and tolerability of ablative 5-fraction stereotactic body radiation therapy (SBRT) administering a biologically effective dose (BED, α/β = 10) ≥ 100 Gy in patients with inoperable, non-metastatic pancreatic cancer (PC).
[MATERIALS/METHODS] We retrospectively reviewed a prospective registry of 88 patients with inoperable non-metastatic PC who underwent ablative 5-fraction SBRT using a CyberKnife with fiducial-based respiratory tracking between 2016 and 2020. The outcomes included overall survival (OS), progression-free survival (PFS), and treatment-related toxicity.
[RESULTS] The cohort included 55 men and 33 women (median age, 65 years; range, 36-84 years). At diagnosis, 29 patients were medically inoperable, and 59 had locally advanced PC (LAPC). SBRT was administered at 50 Gy/5 fractions in 82 patients and 55 Gy/5 fractions in 6 patients. The median gross tumor volume was 33.6 cm (range, 3.7-167.8). With a median follow-up of 64.0 months, the median OS (mOS) was 18.1 months (95 % confidence interval [CI], 16.6-27.1) from the time at diagnosis and 15.6 months (95 % CI, 14.1-23.4) from the start of SBRT. The 1-, 2-, and 3-year OS rates were 73.9 %, 39.8 %, and 26.1 % from diagnosis, and 64.0 %, 36.0 %, and 22.1 % from SBRT, respectively. The mOS from the time at diagnosis was 18.2 months (95 % CI, 17.0-37.1) for medically inoperable patients and 17.1 months (95 % CI, 15.9-28.9) for those with LAPC, with corresponding 1-, 2-, and 3-year OS rates of 86.2 %, 41.4 %, and 31.0 % vs. 67.8 %, 39.0 %, and 23.7 %, respectively. From the start of SBRT, corresponding mOS was 16.2 months (95 % CI, 15.0-35.9) for medically inoperable patients and 14.4 months (95 % CI, 11.0-23.7) for LAPC, with 1-, 2-, and 3-year OS rates of 75.9 %, 37.9 %, and 27.6 % vs. 57.6 %, 33.9 %, and 18.6 %, respectively. Grade 3 gastrointestinal bleeding occurred in four patients (4.5 %), with no grade ≥ 4 toxicities observed.
[CONCLUSION] Ablative 5-fraction SBRT with BED ≥ 100 Gy results in favorable survival and acceptable toxicity in inoperable, non-metastatic PC.
[MATERIALS/METHODS] We retrospectively reviewed a prospective registry of 88 patients with inoperable non-metastatic PC who underwent ablative 5-fraction SBRT using a CyberKnife with fiducial-based respiratory tracking between 2016 and 2020. The outcomes included overall survival (OS), progression-free survival (PFS), and treatment-related toxicity.
[RESULTS] The cohort included 55 men and 33 women (median age, 65 years; range, 36-84 years). At diagnosis, 29 patients were medically inoperable, and 59 had locally advanced PC (LAPC). SBRT was administered at 50 Gy/5 fractions in 82 patients and 55 Gy/5 fractions in 6 patients. The median gross tumor volume was 33.6 cm (range, 3.7-167.8). With a median follow-up of 64.0 months, the median OS (mOS) was 18.1 months (95 % confidence interval [CI], 16.6-27.1) from the time at diagnosis and 15.6 months (95 % CI, 14.1-23.4) from the start of SBRT. The 1-, 2-, and 3-year OS rates were 73.9 %, 39.8 %, and 26.1 % from diagnosis, and 64.0 %, 36.0 %, and 22.1 % from SBRT, respectively. The mOS from the time at diagnosis was 18.2 months (95 % CI, 17.0-37.1) for medically inoperable patients and 17.1 months (95 % CI, 15.9-28.9) for those with LAPC, with corresponding 1-, 2-, and 3-year OS rates of 86.2 %, 41.4 %, and 31.0 % vs. 67.8 %, 39.0 %, and 23.7 %, respectively. From the start of SBRT, corresponding mOS was 16.2 months (95 % CI, 15.0-35.9) for medically inoperable patients and 14.4 months (95 % CI, 11.0-23.7) for LAPC, with 1-, 2-, and 3-year OS rates of 75.9 %, 37.9 %, and 27.6 % vs. 57.6 %, 33.9 %, and 18.6 %, respectively. Grade 3 gastrointestinal bleeding occurred in four patients (4.5 %), with no grade ≥ 4 toxicities observed.
[CONCLUSION] Ablative 5-fraction SBRT with BED ≥ 100 Gy results in favorable survival and acceptable toxicity in inoperable, non-metastatic PC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (2)
- Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy for advanced pancreatic cancer.
- Survival benefits of radiotherapy in locally advanced unresectable and metastatic pancreatic cancer: a single-institution cohort and SEER database analysis.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.